<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In our previous study, we demonstrated that a <z:chebi fb="7" ids="16670">peptide</z:chebi> derived from the novel centrosome residing protein Cep55/c10orf3 can be targeted by the cytotoxic T lymphocytes (CTLs) in peripheral blood mononuclear cells (PBMCs) of <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo> patients </plain></SENT>
<SENT sid="1" pm="."><plain>In this report, we evaluated the feasibility of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> immunotherapy using Cep55/c10orf3 <z:chebi fb="7" ids="16670">peptide</z:chebi> for colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>To evaluate the expression of Cep55/c10orf3 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues, we performed immunohistochemical staining of using anti-Cep55/c10orf3 monoclonal antibody </plain></SENT>
<SENT sid="3" pm="."><plain>Sixty-three percent cases showed weak positive for Cep55/c10orf3 in total 70 CRC cases </plain></SENT>
<SENT sid="4" pm="."><plain>The Cep55/c10orf3 expression intention was collated with high histological grade of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, we hypothesized that Cep55/c10orf3 can also be the target of CTLs in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases </plain></SENT>
<SENT sid="6" pm="."><plain>We generated CTLs from PBMCs of human leukocyte antigen (HLA)-A24-positive colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> patients using HLA-A24-restricted Cep55/c10orf3 <z:chebi fb="7" ids="16670">peptides</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Two of 6 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients were reactive for the Cep55/c10orf3_193(10) <z:chebi fb="7" ids="16670">peptide</z:chebi>, which was the only immunogenic <z:chebi fb="7" ids="16670">peptide</z:chebi> in <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo> patients </plain></SENT>
<SENT sid="8" pm="."><plain>CTL clone specific for Cep55/c10orf3_193(10) recognized and lysed HLA-A24 (+) and Cep55/c10orf3 (+) colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cell lines </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, 1 of 6 colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> patients was reactive for the Cep55/c10orf3_402(11) and Cep55/c10orf3_283(12) <z:chebi fb="7" ids="16670">peptides</z:chebi>, but not for Cep55/c10orf3_193(10) with the ELISPOT assay </plain></SENT>
<SENT sid="10" pm="."><plain>These observations suggest that the antigenic <z:chebi fb="7" ids="16670">peptide</z:chebi> repertoire presented by HLA-A24 in colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> might be different from that in <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Thus, these <z:chebi fb="7" ids="16670">peptide</z:chebi> vaccination <z:chebi fb="7" ids="16670">peptide</z:chebi> mixture of Cep55/c10orf3_193(10), Cep55/c10orf3_402(11) and Cep55/c10orf3_283(12) might be more effective than a single <z:chebi fb="7" ids="16670">peptide</z:chebi> in the treatment of colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> patients </plain></SENT>
</text></document>